title: Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?
authors.forename: David
authors.initials: D
authors.lastname: Grimwade
authors.forename: Martin S
authors.initials: MS
authors.lastname: Tallman
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D008991:Monitoring, Physiologic / Q000379:methods*; D018365:Neoplasm, Residual
chemical_list: D000970:Antineoplastic Agents